These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19641215)

  • 1. Telaprevir for chronic HCV infection.
    van der Meer AJ; de Knegt RJ
    N Engl J Med; 2009 Jul; 361(5):533-4; author reply 534-5. PubMed ID: 19641215
    [No Abstract]   [Full Text] [Related]  

  • 2. [New triple therapy in chronic hepatitis C. Increased patient chances].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
    [No Abstract]   [Full Text] [Related]  

  • 3. Study Results Support Telaprevir-Based Therapy for HCV.
    AIDS Patient Care STDS; 2010 Nov; 24(11):746. PubMed ID: 21108519
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 5. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash.
    Dupin N; Mallet V; Carlotti A; Vallet-Pichard A; Pol S
    Hepatology; 2012 Jun; 55(6):2042-3. PubMed ID: 22234749
    [No Abstract]   [Full Text] [Related]  

  • 7. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
    Serfaty L
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B202-5. PubMed ID: 12180289
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon-alpha.
    Antonelli G; Riva E; Maggi F; Vatteroni ML; Simeoni E
    J Infect Dis; 1999 Oct; 180(4):1411-2. PubMed ID: 10479188
    [No Abstract]   [Full Text] [Related]  

  • 10. [Studies with telaprevir].
    MMW Fortschr Med; 2011 Jul; 153(29-31):15. PubMed ID: 21830727
    [No Abstract]   [Full Text] [Related]  

  • 11. Telaprevir to boceprevir switch highlights lack of cross-reactivity.
    Carlson A; Gregorich Z; Striker R
    Clin Infect Dis; 2013 Feb; 56(4):552-4. PubMed ID: 23166191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Jul; 4(7):24-9. PubMed ID: 11365638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of HCV treatment: who does well and who does not?
    Hsu CS; Kao JH
    J Gastroenterol Hepatol; 2010 May; 25(5):846-8. PubMed ID: 20546434
    [No Abstract]   [Full Text] [Related]  

  • 17. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.
    Toyota J; Ozeki I; Karino Y; Asahina Y; Izumi N; Takahashi S; Kawakami Y; Chayama K; Kamiya N; Aoki K; Yamada I; Suzuki Y; Suzuki F; Kumada H
    J Viral Hepat; 2013 Mar; 20(3):167-73. PubMed ID: 23383655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of patients with chronic hepatitis C who have not been previously treated].
    Marcellin P; Boyer N
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B194-201. PubMed ID: 12180288
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.